KEDRAB® (Rabies Immune Globulin [Human]) is a biologic prepared by chromatographic fractionation from a pool of plasma collected from selected US adult human donors who have been immunized with rabies vaccine and have developed high titers of anti-rabies antibody.1

KEDRAB Is Manufactured Using 3 Specific Steps of Viral Inactivation/Removal2

Solvent/detergent treatment

Heat treatment


KEDRAB is derived from human plasma; therefore, the potential exists that KEDRAB administration may transmit infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.2


KEDRAB Formulary Monograph

Get detailed information about the rabies virus, current post-exposure prophylaxis guidelines, and the efficacy and safety of KEDRAB for rabies exposure.

Kamada and Kedrion Biopharma Have Partnered for the Clinical Development and Marketing of KEDRAB in the US3

Significant Clinical Experience:

  • KEDRAB has been sold and marketed as KamRAB® (Rabies Immune Globulin [Human]) in multiple countries outside the US
  • Since 2003, more than 1.8 million vials of KamRAB has been sold in more than 20 counties outside the US, including Canada, Israel, India, Thailand and Russia, demonstrating significant clinical experience
  • Manufactured in Israel by Kamada

Enroll for Rabies Updates

If you are interested in receiving the most current information about KEDRAB, proper PEP, and educational rabies resources, enroll now.

References: 1. Data on file. Kamada Ltd. 2. KEDRAB [package insert]. Fort Lee, NJ: Kedrion Biopharma Inc.; 2021. 3. FDA acceptance of BLA submission for human rabies immunoglobulin [press release]. Fort Lee, NJ/Ness Ziona, Israel: November 8, 2016.